Table 2.
Treatment-Emergent AEs in Study Eyes (Safety Population)
| AE, n (%)* | DEX (N = 145) | Laser (N = 129) |
|---|---|---|
| Overall† | 93 (64.1) | 45 (34.9) |
| Increased IOP | 49 (33.8) | 4 (3.1) |
| Cataract | 22 (15.2) | 8 (6.2) |
| Visual impairment | 8 (5.5) | 15 (11.6) |
| Conjunctivitis | 11 (7.6) | 1 (0.8) |
| Ocular hypertension | 10 (6.9) | 1 (0.8) |
| Dry eye | 8 (5.5) | 7 (5.4) |
| Vitreous hemorrhage | 6 (4.1) | 6 (4.7) |
Notes: *All individual treatment-emergent AEs reported in the study eye of ≥3% of patients in either treatment group are listed. All AEs were reported by the investigators based on their clinical expertise and judgement, †Any treatment-emergent AE in the study eye.
Abbreviations: AE, adverse event; DEX, dexamethasone intravitreal implant 0.7 mg; IOP, intraocular pressure.